MedPath
FDA Approval

Halaven

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
November 22, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Eribulin(0.5 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

BSP Pharmaceuticals SpA

857007830

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

BSP Pharmaceuticals SpA

BSP Pharmaceuticals SpA

BSP Pharmaceuticals SpA

857007830

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Halaven

Product Details

NDC Product Code
43624-002
Application Number
NDA201532
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
November 22, 2023
EribulinActive
Code: AV9U0660CWClass: ACTIBQuantity: 0.5 mg in 1 mL
ALCOHOLInactive
Code: 3K9958V90MClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath